** Shares of drugmaker SpringWorks Therapeutics SWTX.O rise 10.12% to $61.37 premarket
** Co says it will not host a conference call to discuss its quarterly earnings, which Evercore ISI analysts say confirms that its negotiations with Germany's Merck KGaA MRCG.DE for a potential buyout "are still very much alive"
** Reuters reported on February 10 that Germany's Merck KGaA MRCG.DE was in advanced talks to acquire the company; Merck subsequently confirmed the talks
** Separately, SpringWorks posts Q4 revenue of $61.5 mln, versus analysts' est of $59.1 mln, as per data compiled by LSEG
** "This morning's 4Q print is in-line (recall January pre-announcement) and irrelevant," says Evercore ISI
** Stock has risen 3.2% since the Reuters report and 13.5% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。